Charles River Laboratories International, Inc. (CRL) stock
CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30225% above fair value
$333.25+1.09 (+0.33%)
Close on Nov 18, 2026Market cap $15.91BP/E –Yield –
Charles River Laboratories International pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Charles River Laboratories International's pe ratio was 403.2× on Nov 11, 2026, against 24.4× a year earlier. Over the last 5 years it ranged from 17.9× to 826.5×, with a median of 28.7×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 403.2× | −189.9 |
| 2025 | Apr 30, 2025 | 593.1× | +570.1 |
| 2024 | Dec 31, 2024 | 23.0× | −2.6 |
| 2023 | Dec 29, 2023 | 25.6× | −0.1 |
| 2022 | Dec 30, 2022 | 25.7× | −23.0 |
| 2021 | Dec 31, 2021 | 48.7× | +7.0 |
| 2020 | Dec 31, 2020 | 41.6× | +8.9 |
| 2019 | Dec 31, 2019 | 32.8× | −8.1 |
| 2018 | Dec 31, 2018 | 40.9× | +14.2 |
| 2017 | Dec 29, 2017 | 26.7× | +1.0 |
| 2016 | Dec 30, 2016 | 25.7× | −0.8 |
| 2015 | Dec 31, 2015 | 26.4× | +0.9 |
| 2014 | Dec 31, 2014 | 25.6× | +0.4 |
| 2013 | Dec 31, 2013 | 25.1× | +8.0 |
| 2012 | Dec 31, 2012 | 17.1× | −73.4 |
| 2011 | Jan 31, 2011 | 90.5× | +6.6 |
| 2010 | Dec 31, 2010 | 83.8× | – |
See a number that looks wrong?